Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Food And Drug Administration Accepts Allergan PLC (AGN) Vraylar For Review As A Supplemental Drug

Allergan plc Ordinary Shares (NYSE:AGN) has announced that an application to have new clinical data for Vraylar evaluated has been accepted by the Food and Drug Administration of the United States.

The new clinical data that is set to be evaluated shows evidence that Vraylar may be effective in schizophrenia’s maintenance treatment. This is because there is a high rate of relapse when it comes to schizophrenic patients who are not on any kind of psychotic treatment.

Allergan Beauty Products Avon AGN ACT AVP lip closeup syringe skincare recovery silicone hyaluronic

evgeny varlamov /

“Most patients with schizophrenia are at very high risk of relapse in the absence of antipsychotic treatment. Without maintenance treatment, 60–70 percent of patients relapse within one year, and almost 90 percent relapse within two years,” Herbert Meltzer, a psychiatry professor at Northwestern School of Medicine said.

Open-Label Phase

The new data was gathered from a Phase III study that was placebo-controlled, double-blind, randomized and multinational. Participants who were put on Vraylar (cariprazine) took longer to relapse compared to patients who were taking a placebo. In the course of the study, a period of 20 weeks was used as an open-label phase during which participants suffering from schizophrenia received cariprazine in doses of either 3, 6, or 9 grams. The participants who responded positively and who were able to stabilize were then randomly placed on a placebo or cariprazine with the primary endpoint being to observe first symptom relapse.

From the study it was observed that the rate of relapse in participants who were on placebo was double that of the patients who were on cariprazine.

Gedeon Richter

Cariprazine got the approval of the Food and Drug Administration in 2015. In the United States, it is marketed under the Vraylar brand name and is used for the treatment of bipolar disorder as well as schizophrenia in adults. The drug is taken orally and the recommended dosage is usually once a day. Gedeon Richter initially discovered vraylar and also co-developed it. Allergan plc Ordinary Shares (NYSE:AGN) has the license for the drug in both Canada and the United States.

Follow Allergan Plc (NYSE:AGN)
Trade (NYSE:AGN) Now!

Note: This article is written by Andy Parker and was originally published at Market Exclusive.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.